Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;15(1):127-130.
doi: 10.3892/etm.2017.5377. Epub 2017 Oct 26.

The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease

Pei-Lan Zhang  1 , Yu-Xin Wang  1 , Yan Chen  1 , Chen-Hao Zhang  1 , Chen-Hua Li  1
Affiliations

The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease

Pei-Lan Zhang et al. Exp Ther Med. 2018 Jan.

Abstract

The aim of the study was to investigate the efficacy of homemade tolcapone in treatment of patients with Parkinson's disease (PD). Eighty patients with PD were subjected to randomized, double-blind, placebo-controlled and parallel-group study. PD patients were randomly divided into the tolcapone treatment group (41 cases) and placebo group (39 cases). Each patient received 1 pill of tolcapone or placebo, 3 times per day for 26 weeks. Efficacy was evaluated using the internationally used unified Parkinson's disease rating scale (UPDRS) scoring system for PD symptoms. After the treatment for 26 weeks, the cognitive function, tremor, muscle stiffness, voluntary movement and autonomic nerve symptoms were compared between the two groups using UPDRS scores. Compared with the placebo group, cognitive function, muscle stiffness and voluntary movement reduction were significantly improved in patients of the tolcapone group (P<0.05). However, no significant differences in UPDRS scores of autonomic nerve symptoms and tremor were found between two groups after treatment (P>0.05). Tolcapone, a catechol-O-methyl transferase (COMT) inhibitor, can improve the motor function of patients with PD, especially exercise and muscle stiffness. Tolcapone can also improve the cognitive function of patients.

Keywords: Parkinsons disease; catechol-o-methyl transferase inhibitor; tocapine; tolcapone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry. 1994;57:672–681. doi: 10.1136/jnnp.57.6.672. - DOI - PMC - PubMed
    1. Zulli C, Sica M, De Micco R, Del Prete A, Amato MR, Tessitore A, Ferraro F, Esposito P. Con-tinuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: A preliminary study. Eur Rev Med Pharmacol Sci. 2016;20:2413–2417. - PubMed
    1. Wu L, Mu N, Yang F, Zang J, Zheng JP. A study of the non-motor symptoms in early Parkinson's disease with olfactory deficits. Eur Rev Med Pharmacol Sci. 2016;20:3857–3862. - PubMed
    1. Fahn S. Tolcapone: COMT inhibition for the treatment of Parkinson's disease. Neurology. 1998;50(Suppl 5):S1–S2. doi: 10.1212/WNL.50.5_Suppl_5.S1. - DOI - PubMed
    1. Grünig D, Felser A, Bouitbir J, Krähenbühl S. The catechol-O-methyltransferase inhibitors tolcapone and entacapone uncouple and inhibit the mitochondrial respiratory chain in HepaRG cells. Toxicol In Vitro. 2017;42:337–347. doi: 10.1016/j.tiv.2017.05.013. - DOI - PubMed
-